Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Hannah Willis, Joshua Horns, Kelsey Baron, Allison Bock, Lindsey Fitzgerald, Narendranath Epperla, Harsh Shah, Boyu Hu, Deborah Stephens, Adam Kittai, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2025-6316

Published: 2025

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Blood (2025) 146 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2025-4514

Published: 2025

Journal Articles

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer, Robert Ryan, Ajay Major, Natalie Grover, Kelsey Baron, Talal Hilal, Adrienne Nedved, Taylor Brooks, Arjun Ravishankar, Tarsheen Sethi, Brian Hill, Yucai Wang, Allison Bock, Adam Kittai, Matthew Matasar, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2025-1956

Published: 2025

Journal Articles

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Narendranath Epperla, Allison Bock, Yizhe Xu, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Kelsey Baron, Daniel Ermann, Joe Mendez, Lindsay Burt, Donald Cannon, Amit Maity, Joshua Palmer, Iyad Alnahhas, Thomas Ollila

Blood (2025) 146 (Supplement 1): 8241.

https://doi.org/10.1182/blood-2025-8241

Published: 2025

Journal Articles

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Narendranath Epperla, Yizhe Xu, Allison Bock, Kelsey Baron, Lindsey Fitzgerald, Harsh Shah, Daniel Ermann, Lalit Sehgal, Lapo Alinari, Boyu Hu

Blood (2025) 146 (Supplement 1): 8235.

https://doi.org/10.1182/blood-2025-8235

Published: 2025

Journal Articles

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

Narendranath Epperla, Allison Bock, Boyu Hu, Yizhe Xu, Lindsey Fitzgerald, Daniel Ermann, Harsh Shah, Kelsey Baron, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 3616.

https://doi.org/10.1182/blood-2025-3616

Published: 2025

Journal Articles

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Kelsey Baron, Charlotte Wagner, Lindsey Fitzgerald, Amber Jacoway, Ausha Marden, Daniel Ermann, Boyu Hu, Harsh Shah, Narendranath Epperla, Allison Bock

Blood (2025) 146 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2025-4485

Published: 2025

Journal Articles

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

XI Yang, Henry Dumke, Joseph Schroers-Martin, Yazeed Sawalha, Sree Lanka, Izel Okcu, Grzegorz Nowakowski, Peter Doukas, Reem Karmali, Meryl Colton, Michael Spinner, Vincenzo Pizzuti, Manali Kamdar, Olutobi Adewale, Yun Kyoung Tiger, Kelsey Baron, Allison Bock, Marcus Geer, Yasmin Karimi

Blood (2025) 146 (Supplement 1): 783.

https://doi.org/10.1182/blood-2025-783

Published: 2025

Journal Articles

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Amanda Chron, Kelsey Baron, Ashlee Joseph, Ayushi Chauhan, Sonia Godbole, Andrew Jallouk, Amy Ayers, Ajay Major, Swetha Thiruvengadam, Narendranath Epperla, Shakthi Bhaskar, Alex Herrera, Yazeed Sawalha, Sairah Ahmed, Gilles Salles, Lorenzo Falchi, Allison Bock

Blood (2025) 146 (Supplement 1): 958.

https://doi.org/10.1182/blood-2025-958

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Blood (2023) 142 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2023-173470

Published: 2023

Journal Articles

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Robert Stuver, Esther Drill, Nivetha Ganesan, Kelsey Baron, Ellie Casper, Tiffany Chang, Sanjal H. Desai, Ayo S Falade, Natasha Galasso, Alex F. Herrera, Matthew G. Mei, Reid W. Merryman, Ivana Micallef, Harsh Shah, Alison Moskowitz

Blood (2023) 142 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2023-182143

Published: 2023

Journal Articles

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Blood (2023) 142 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2023-182318

Published: 2023

Journal Articles

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Blood (2023) 142 (Supplement 1): 182.

https://doi.org/10.1182/blood-2023-179573

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only